ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Despite its promise, the efficacy of CAR T-cell therapy remains limited, with durable remissions being achieved in only 40% of diffuse large B-cell lymphoma patients (17). Enhancing the design of chimeric antigen receptor (CAR) constructs is a critical area of research aimed at augmenting the efficacy of CAR T-cell therapies. This effort involves the engineering of CARs with advanced signaling capabilities and the integration of safety features to address the limitations observed with first-and second-generation CAR T cells (18).

A range of innovative strategies focusing on the refinement of CAR constructs and optimization of manufacturing protocols have emerged. For example, multiplexed CARs targeting multiple tumor-associated antigens aim to forestall tumor escape mechanisms by addressing antigen loss or heterogeneity (19, 20). Similarly, the development of “modular” or “universal” CAR systems offers adaptable targeting capabilities through switchable, bispecific adaptors, enhancing the precision of CAR T-cell engagement with diverse tumor antigens (21–26). Furthermore, synthetic Notch (SynNotch) receptors represent a cutting-edge advancement in CAR T cell engineering, employing a dual antigen recognition strategy for activation. This novel approach uses SynNotch receptors to initiate transcription of a CAR after interacting with a predefined primary antigen, ensuring activation is strictly tumor specific (27–29). This two-step activation process allows for more precise tumor targeting and minimizes off-tumor activity, enhancing safety and reducing potential toxicities associated with conventional CAR T cell therapies. In addition to these innovations, Hybrid CARs technologies combine features from both T-cell receptors (TCRs) and CARs to enhance the targeting of cancer-specific antigens and reduce tonic signaling, enabling the engineered cells to recognize and engage with intracellular antigens presented at ultra-low densities on cancer cells by MHC molecules (30–36). This advancement will potentially broaden the therapeutic applicability of CAR technology, allowing it to target the entire proteome of a cancer cell.

Advancements in CAR T-cell design have led to the development of “third generation” CAR T cells, which represent a next-generation approach aiming to enhance the efficacy and longevity of these therapies. By integrating multiple co-stimulatory molecules into the CAR structure, these sophisticated constructs are designed to provide enhanced activation and sustained support to the CAR T cells (37, 38). Additionally, “armored” CAR T cells are genetically modified to enhance their efficacy and persistence. These modifications allow armored CAR T-cells to secrete active cytokines or express other pro-inflammatory ligands to enhance their anti-tumor activity, helping them better survive, disrupt, and modulate the tumor microenvironment, improving their function in hostile conditions (39–41).

In the pursuit of enhancing the efficacy and persistence of CAR T-cell therapies, researchers have innovated and refined manufacturing protocols. The integration of CRISPR/Cas9 gene editing represents a revolutionary stride in CAR T cell manufacturing. This precise gene-editing technology allows for the specific deletion of CAR T genes in an effort to bolster CAR T cell persistence and functionality, such as the knockout of genes encoding inhibitory receptors (42), epigenetic modifiers (43), and those mediating CAR T exhaustion (44). In parallel, advancements in vector technology have substantially improved the delivery of genetic material into T cells (45). Viral vectors, known for their high efficiency in gene delivery, have been optimized to enhance transduction rates while minimizing the risk of insertional oncogenesis—a concern with earlier-generation vectors especially retroviral vectors (46). Modern lentiviral and retroviral vectors offer stable gene transfer, which is crucial for the long-term expression of CAR genes (47). Non-viral engineering strategies have also progressed, offering more scalable and potentially safer alternatives to viral methods (48). These include transposon-based systems like Sleeping Beauty (49), which enable stable gene integration, and mRNA electroporation (50), which provides a transient expression that can be advantageous for safety. Additionally, non-viral methods such as the CRISPR complex delivery system for manufacturing CAR T cells offers enhanced safety by avoiding viral vector risks and ensuring precise gene editing without affecting other genome areas, thus minimizing off-target effects. The technology is also versatile, allowing for both gene knock-ins and knock-outs, enhancing the functional capabilities of CAR T cells and their therapeutic efficacy and safety (51, 52) Table 2.

The strategic selection of specific T cell subsets is pivotal in honing the efficacy of CAR T cell therapies. Central memory T cells (Tcm) and stem cell-like memory T cells (Tscm) are being employed due to their inherent longevity, robust proliferative abilities, and potent antitumor responses (53). These cells are known for their self-renewal capacity and long-term memory, providing a persistent immunological presence against tumors. Leveraging these subsets is instrumental in creating a pool of CAR T cells with superior proliferative capacity, long-term persistence, and potent antitumor activity (54, 55). Additionally, the inclusion of both CD4+ and CD8+ T cells could further enhance the therapeutic potential of CAR T-cell constructs. CD4+ T cells, often termed helper T cells, are crucial for their supportive role in immune modulation and enhancing the function of CD8+ T cells, which are primarily responsible for executing cytotoxic actions against tumor cells. Incorporating both subtypes not only facilitates a robust and sustained antitumor immune response but also capitalizes on the synergistic interactions between them to maximize therapeutic outcomes (56–58) Table 3.

Interdisciplinary approaches are crucial in advancing CAR T-cell therapy by integrating insights from bioinformatics, materials science, immunology, single-cell studies, and various omics technologies. Bioinformatics plays a pivotal role in analyzing large-scale genomic and proteomic data to identify new targets (59) and understand complex cellular behaviors (60, 61). Furthermore, single-cell technologies and omics analyses enable the detailed study of individual cell behaviors and responses, providing a more nuanced understanding of the variability and efficacy of CAR T-cell therapies (62). These interdisciplinary efforts are vital for tailoring therapies to individual patients’ unique biological contexts, ultimately enhancing the precision and effectiveness of CAR T-cell treatments (Figure 2).

The integration of synthetic biology and advanced engineering in CAR T-cell therapy brings forth transformative prospects for improving therapeutic efficacy and safety. However, this progress is accompanied by substantial challenges and controversies. Innovations such as multiplexed, modular, and SynNotch CAR systems provide unprecedented precision in tumor targeting, potentially reducing off-target effects and enhancing treatment specificity. Despite these advancements, the complexity and novel nature of these designs prompt concerns about their predictability and consistent performance in diverse clinical scenarios. The scientific community continues to debate the ideal balance between the sophistication of these designs and the practicalities of manufacturing, scalability, and regulatory approvals. Ethical considerations and the dynamic nature of regulatory standards further complicate the rapid adoption and implementation of these advanced therapies. Importantly, there is a critical need for comprehensive clinical trials to rigorously evaluate the long-term safety and efficacy of these next-generation CAR T cells. Such trials are essential to ensure that these innovative treatments can be safely integrated into clinical practice and can deliver sustained benefits to patients. As research progresses, streamlining manufacturing processes and establishing robust and more cost-effective regulatory frameworks will be pivotal in overcoming current limitations. Together, these steps will help to unlock the full potential of CAR T-cell therapies, extending their benefits beyond hematologic malignancies to include the effective treatment of solid tumors.

In the advancement of CAR T-cell therapy, a key focus has been on identifying and targeting new antigens to expand the therapy’s efficacy across diverse cancer types. Researchers are exploring tumor-specific antigens (TSAs) and neoantigens that are unique to cancer cells, minimizing off-target effects and personalizing treatment (63–67). Oncoviral proteins (68, 69) and cancer testis antigens (CTAs) and other embryonic antigens (70, 71) provide new targets, especially in cancers associated with viral infections and limited normal tissue expression, respectively.

Targeting cancer stem cells (CSCs) with CAR T cell therapy is an emerging strategy aimed at eradicating the root of tumor regrowth and metastasis. CSCs are elusive targets due to their low abundance and expression of conventional antigens, but their role in driving tumor progression and recurrence makes them logical targets (72, 73). CAR T cells are being engineered to recognize CSC-specific antigens to selectively target and eliminate these progenitor cells, potentially leading to more durable responses and reducing the likelihood of cancer relapse (74–77).

The pursuit of targeting novel antigens in CAR T-cell therapy represents a cutting-edge approach that holds promise for enhancing treatment specificity and expanding efficacy across diverse cancer types. While the use of tumor-specific antigens and neoantigens offers a pathway toward more personalized and less toxic treatments, significant challenges remain. Identifying and validating effective targets that are unique to cancer cells without affecting normal tissue is complex and requires rigorous testing. Furthermore, the targeting of cancer stem cells, though promising for preventing recurrence, presents issues of selectivity and safety due to their low abundance and heterogeneity. Continued advancements in antigen discovery, coupled with an integrative approach that combines CAR T-cell therapy with other treatment modalities, are critical for overcoming current limitations and fully realizing the potential of this powerful therapeutic tool.

Addressing the formidable challenges posed by solid tumors necessitates innovative strategies in CAR T-cell therapy, focusing on two critical areas: enhancing homing and penetration, and overcoming the immunosuppressive tumor microenvironment (TME). Solid tumors present a unique set of barriers, including a dense extracellular matrix and a hostile TME characterized by immune-suppressive cells and factors. To improve CAR T-cell homing, research has pivoted towards engineering CAR T cells to express specific chemokine receptors that match the chemokines secreted by tumors, thereby enhancing their trafficking and infiltration capabilities (78, 79). Furthermore, modifications are being explored to facilitate penetration through the tumor’s dense matrix by incorporating matrix-degrading enzymes into CAR T-cell designs (80, 81). Another emerging strategy is targeting tumor vasculature with CAR T cells engineered to attack specific endothelial markers which offers a dual benefit: direct tumor starvation and enhanced immune cell infiltration, boosting antitumor efficacy (82).

Simultaneously, strategies to counteract the immunosuppressive effects of the TME are critical. This includes the development of “armored” CAR T cells capable of secreting cytokines to modulate the TME, making it more conducive to T-cell activity, as discussed in the previous section (39–41). Additionally, various genetic modifications are being considered, including the design of PD-1–CD28 switch receptors (83), which are engineered to convert inhibitory signals into stimulatory ones, and the knockdown of intracellular inhibitors (84) to maintain CAR T-cell activation and effector functions. Metabolic adaptation is also key, where CAR T cells are engineered to withstand the nutrient deprived and hypoxic TME (85). Enhancements to the CAR T metabolic pathways enable them to maintain functionality and survive in the harsh tumor conditions (86, 87). In addition, there’s a growing interest in inhibiting tumor-derived exosomes, which often carry immunosuppressive molecules (88). By preventing these exosomes from reaching and impairing CAR T cells, it’s possible to preserve the T cells’ vigor and anti-tumor activity, further bolstering their effectiveness against solid tumors.

Local delivery of CAR T cells is an innovative method where CAR T cells are administered directly into the tumor site, offering a concentrated attack while potentially reducing systemic toxicity (89, 90). This targeted approach may improve the efficiency of CAR T-cell penetration and functionality within the solid tumor microenvironment. Advancing this concept, researchers are leveraging nanotechnology to develop novel delivery systems. These nano-carriers can protect CAR T cells during transit, enhance their migration and infiltration into tumors, and provide controlled release mechanisms, which could lead to improved persistence and efficacy of the CAR T cells (91, 92).

The innovative strategies being developed to enhance CAR T-cell therapy in solid tumors—focusing on improved homing, penetration, and overcoming the immunosuppressive microenvironment—represent significant advances in the field. While engineering CAR T cells to express specific chemokine receptors and matrix-degrading enzymes shows promise in enhancing infiltration into solid tumors, the complexity and heterogeneity of these tumors pose substantial challenges. The development of ‘armored’ CAR T cells and other genetically modified cells intended to modulate the hostile TME is progressing, yet concerns about safety, specificity, and long-term effects remain. Debates within the scientific community regarding the practicality of these complex interventions versus simpler, more robust approaches underscore the need for a balanced exploration of these technologies. Extensive clinical trials and continuous technological improvements are crucial to validate these strategies and ensure they can be safely and effectively integrated into patient care.

The integration of CAR T-cell therapy with other cancer treatment modalities is at the forefront of innovative strategies aimed at overcoming existing barriers in immunotherapy and CAR T cell therapy. Research is actively pursuing the synergistic potential of CAR T therapy alongside immune checkpoint inhibitors (ICIs), which are known to rejuvenate exhausted T cells and enhance the immunogenicity of the tumor microenvironment (93, 94). This combination is particularly promising in solid tumors, where ICIs alone have shown limited efficacy. Numerous clinical trials are evaluating the efficacy of combining CAR T cells with ICIs like PD-1 and CTLA-4 inhibitors to potentiate the anti-tumor response while aiming to mitigate immune-related adverse events (95, 96).

Moreover, the strategic use of targeted therapies such as tyrosine kinase inhibitors (TKIs) alongside CAR T cells is another area of exploration (97). TKIs can modulate key signaling pathways within both tumor cells and T cells, potentially enhancing the CAR T cells’ ability to persist and remain active in hostile tumor environments (97, 98). This approach is being tested in various hematologic and solid tumors, with early trials showing promising enhancements in CAR T cell functionality and overall survival rates (98) (NCT04257578↗, NCT04484012↗).

Additionally, other targeted therapies like DNA damage repair inhibitors, which sensitize cancer cells to immunotherapy and promote infiltration (99), and angiogenesis inhibitors, which can alter the tumor microenvironment to improve T cell infiltration and function (100), are being investigated. The combination of CAR T cells with BRAF and MEK inhibitors (101), EZH2 inhibitors (102), lenalidomide (103) and others could potentially lead to synergistic anti-tumor effects, further enhancing the efficacy of CAR T cell therapies in complex oncological landscapes.

Low-dose chemotherapy is also employed in combination with CAR T therapy as a bridging therapy, conditioning regimen, or neoadjuvant and adjuvant treatment (104). Lymphodepletion prior to CAR T cell therapy not only creates space for CAR T cells to expand but also reduces the immunosuppressive regulatory cells, thereby boosting the efficacy of CAR T cells post-infusion (105, 106). The timing, dosage, and type of chemotherapeutic agents are critical aspects currently under clinical investigation to optimize this synergy.

Radiation therapy, used concurrently with CAR T-cell therapy, is believed to promote effector T cell recruitment, remodel the tumor vasculature, enhance T cell infiltration, and alter the suppressive nature of the tumor environment (107). This combination is particularly examined in solid tumors to increase local control and potentially generate systemic immune responses (108, 109). However, fractionation, dosing, and timing of radiation should be optimized to maximize the potential therapeutic benefits while minimizing potential risks like radiation-induced T cell apoptosis.

Oncolytic viruses and bispecific T-cell engagers (BiTEs) represent innovative combination partners for CAR T cells as well. Oncolytic viruses can lyse tumor cells, alter the TME to make it more susceptible to immune cell mediated attack, and provoke an innate immune response that may prime the tumor for CAR T cell therapy (110). Multiple studies have demonstrated various degrees of success and the potential of this combinatory approach (111–113). Meanwhile, BiTEs can bridge CAR T cells to tumor cells by targeting two different antigens simultaneously, which could reduce antigen escape and enhance the specificity of the CAR T-cell response (114, 115).

In summary, combining CAR T-cell therapy with other cancer treatments such as ICIs, TKIs, and other targeted therapies is a promising frontier in oncology. While these combinations show potential in enhancing efficacy and overcoming resistance, substantial challenges remain. These include the complexity of treatment regimens, potential for increased toxicity, and the need for meticulously designed clinical trials to determine optimal dosing and scheduling. Further research and interdisciplinary collaboration are crucial to balance innovation with careful evaluation, ensuring these therapies can be safely and effectively integrated into clinical practice, ultimately improving patient outcomes.

Autologous CAR T-cell therapies, while highly personalized, face significant limitations, including treatment delays, complexity, and variability in T-cell quality and quantity, which can affect efficacy. These therapies involve a time-consuming process where a patient’s own T cells are harvested and engineered to express CARs, introducing accessibility issues for patients with rapidly progressing diseases or insufficient T-cell counts. In contrast, allogeneic CAR T cells, derived from healthy donors and manufactured in bulk, provide a ready-to-use solution that can be standardized, potentially leading to more consistent therapeutic outcomes across different patients. This “off-the-shelf” approach offers immediate availability, reduces manufacturing time and costs, and enables rapid deployment in acute clinical settings, making it a more accessible and cost-effective treatment option for a wider patient population Table 4.

However, the application of allogeneic CAR T cells introduces the risk of graft-versus-host disease (GVHD), a serious complication stemming from the donor immune cells attacking the recipient’s body. To mitigate this risk, sophisticated genetic engineering strategies are being employed. These include the knockout of the T-cell receptor (TCR) alpha chain gene or beta chain gene (116–118) to prevent the recognition of host cells by the infused CAR T cells, the use of virus-specific T cells with more restricted TCR repertoire as a source of generating allogeneic CAR T cells (119), and the use of non-αβ T cells, such as NK cells, invariant NK (iNKT), γδ T cells, or CD4/CD8 double negative T cells to engineer CAR cells (120–124).

Allogeneic CAR T-cell therapies face significant challenges in ensuring their evasion of the host immune surveillance and effective expansion and persistence in patients–pivotal for achieving sustained antitumor responses. To specifically target this issue, researchers have innovated by integrating an alloimmune defense receptor (ADR) which targets activated T and NK cells expressing the 4-1BB activation marker, thereby evading immune-mediated rejection while maintaining antitumor efficacy (125). This approach not only enhances CAR T-cell persistence but also minimizes the risk of graft-versus-host disease. Additionally, optimizing lymphodepletion and refining gene editing for T-cell robustness are crucial for overcoming these expansion and persistence challenges in allogeneic CAR T-cell therapy (117, 126).

The transformative potential of allogeneic CAR T-cell therapy lies in its ability to provide standardized, ready-to-use treatments that can be rapidly deployed. Nonetheless, this approach necessitates advanced genetic engineering to prevent immune rejection and GVHD. Addressing these challenges involves navigating complex ethical and regulatory concerns while ensuring long-term safety and efficacy through rigorous clinical trials. Balancing innovation with patient safety will be essential to realize the full potential of allogeneic CAR T cells, making them a viable option for a broader spectrum of patients globally.

In the quest to overcome the toxicities associated with CAR T-cell immunotherapy, several innovative strategies are being employed to enhance safety and control. The integration of “safety switches”, such as inducible caspase-9 (127–130) and antibody-dependent cell-mediated cytotoxicity (ADCC) switches (131), enables the rapid elimination of CAR T cells in the event of severe side effects. Additionally, small molecule-based safety switches have been developed, allowing clinicians to rapidly deactivate the cells if adverse effects occur (132–134). Another promising approach is the use of Split, Universal, and Programmable (SUPRA) CARs, which divide the CAR system into two distinct components that must interact for activation. This design enhances control, enables more precise targeting, and reduces unintended T-cell activation (135, 136).

Similarly, Dual CARs employ a strategy where CAR T cells are engineered to express two distinct receptors, requiring recognition of two specific antigens for activation. This dual recognition system enhances the specificity of CAR T cells, significantly reducing the risk of off-target effects and increasing the safety profile of these therapies (137). Control of CAR expression is achieved using inducible promoters (138, 139) or drug-responsive elements (140, 141), and innovative methods like sound (142) or light (143) activation, allowing for precise temporal and spatial control over CAR expression. This controlled approach helps to minimize the risk of overactivation and associated toxicities.

Local delivery of CAR T cells, which involves administering these cells directly to the tumor site, minimizes systemic exposure and reduces the risk of widespread toxicities often associated with broader systemic administration (89, 144). Prophylactic use of medications such as tocilizumab and anakinra is explored to preemptively reduce the severity of cytokine release syndrome (CRS) and neurotoxicity (145–147). Techniques like biomarker monitoring (148) and fractionated dosing (149) are under investigation to better predict and manage toxic responses by moderating CAR T-cell activity. Furthermore, advancements in cellular engineering, such as CRISPR/Cas9 gene editing, are aimed at enabling CAR T cells to resist activation by certain cytokines that contribute to toxicities (150, 151). Mouse models are also being developed to study the pathogenesis of CRS and neurotoxicity in CAR T-cell therapy, aiding in the identification of key inflammatory pathways and the testing of new safety interventions (14, 152, 153).

The implementation of advanced safety strategies such as safety switches, controlled activation systems, and localized delivery methods represents a significant advancement in mitigating the inherent toxicities of CAR T-cell therapy. These innovations offer enhanced control over CAR T-cell function, potentially reducing severe side effects and improving patient safety. However, these sophisticated mechanisms also introduce greater complexity into therapy design and application, which could impact both the reliability and cost of treatments. The integration of such advanced features necessitates rigorous clinical trials to confirm their efficacy and safety, alongside ethical considerations regarding access and cost. As research progresses, the challenge will be to refine these technologies to ensure they enhance therapeutic outcomes without compromising efficacy, paving the way for safer, more effective CAR T-cell therapies accessible to a wider range of patients.

To tackle the challenges of manufacturing and accessibility in CAR T-cell therapy, researchers are deploying multiple innovative strategies aimed at streamlining production, enhancing efficiency, and reducing costs. Automated manufacturing systems are a pivotal advancement, utilizing closed-system bioreactors that standardize the production process, diminish the risk of contamination, and minimize labor costs. These systems can significantly cut down on the time required to produce therapeutic doses of CAR T cells (154–156), Table 5. Point-of-care manufacturing involves the development of compact, on-site production units within hospital settings, which reduces logistical complexities associated with the transport of cellular materials and shortens the turnaround time from collection to infusion. This approach not only speeds up the treatment process but also aims to lower overall therapy costs (157, 158).

Advanced cell expansion techniques are being developed to improve the yield and functionality of CAR T cells, including optimizing the growth media (159, 160) and conditions in bioreactors (161). Artificial Intelligence (AI) and Machine Learning (ML) have transformative potential in optimizing the production, enhancing accessibility, and reducing the costs of CAR T cell therapy. AI can streamline manufacturing processes through automation and precise control, ensuring consistency and quality while reducing labor costs (162–164). Machine learning models can predict patient outcomes from pre-infusion transcriptomes, outperforming traditional methods (165). Additionally, neural networks help design CAR constructs with optimal signaling motifs, streamlining the development and enhancing the accessibility of these therapies (166).

Economic analysis is integral to the strategies for optimizing CAR T-cell therapy manufacturing, enhancing accessibility, and reducing costs (16, 167). The high cost of CAR T-cell therapies primarily stems from the complexity of the production processes and the personalized nature of the treatments. Strategies to reduce these costs include streamlining manufacturing protocols, employing automated systems, and developing scalable batch processes which can reduce labor costs and minimize errors (16). Economic benefits also arise from shortening production times and reducing the footprint of manufacturing facilities through point-of-care production technologies (157, 158). Furthermore, adopting non-viral gene transfer methods and utilizing less costly reagents can significantly cut production expenses (48). By lowering the cost of goods and improving manufacturing efficiency, these therapies can become more accessible, particularly in low- and middle-income countries, where the burden of treatment costs is most pronounced. Engaging in cooperative strategies with global partners and governments to establish local manufacturing facilities can also reduce transportation costs and tariffs, further driving down prices and expanding access (168, 169). These economic considerations are essential for the widespread adoption of CAR T-cell therapies and require ongoing innovation and investment to ensure that these life-saving treatments are affordable and available to all patients in need, regardless of geographic location.

Efforts to streamline regulatory approvals for new manufacturing facilities and methods are crucial. Engaging with regulatory bodies to simplify and expedite the review and approval processes can significantly decrease the time and financial burden associated with bringing CAR T-cell therapies to market (170–172). Additionally, addressing regulatory and ethical considerations is essential, especially as CAR T-cell therapies involve complex genetic manipulations and personalized treatment protocols. Regulatory frameworks must ensure patient safety, manage ethical concerns related to genetic editing, and handle the implications of using donor cells in allogeneic therapies. Ethical considerations also extend to ensuring equitable access to these potentially life-saving therapies, preventing disparities in healthcare outcomes. Collaborative dialogues with ethicists, patient advocacy groups, and regulators are necessary to navigate these aspects effectively, ensuring that CAR T-cell therapies are not only scientifically sound but also socially responsible and accessible to all segments of the population.

In summary, the innovative strategies aimed at optimizing the production, enhancing accessibility, and reducing the cost of CAR T-cell therapies present significant advancements in the field. Automated manufacturing systems, point-of-care production units, and global manufacturing networks have the potential to standardize treatments, reduce production time, and make therapies more accessible, especially in underserved regions. However, these advances bring complexities, including high initial costs, operational challenges, and significant regulatory hurdles. Moreover, the integration of AI and machine learning promises further optimization but requires careful implementation to ensure quality and efficacy are maintained. As the field progresses, a balanced approach that addresses these technological, regulatory, and ethical challenges will be crucial for realizing the full potential of CAR T-cell therapies, making them a viable option for a broader range of patients globally. This comprehensive strategy will need to continue evolving, guided by ongoing research and adaptation to new insights and technological advancements.

The integration of bioinformatics, materials science, immunology, synthetic biology, genetic engineering, immunogenetics, and biomedical engineering has ushered in a new era of precision in CAR T-cell therapy. The utilization of computational tools to design CAR constructs and predict therapeutic outcomes is revolutionizing how treatments are personalized. Synthetic biology and genetic engineering are enhancing the specificity and efficacy of these constructs, while immunogenetics helps tailor therapies to individual immune system variations. Biomedical engineering contributes to the development of biocompatible materials and advanced delivery systems that improve the in vivo functionality of therapeutic cells. However, the translation of these complex designs from the bench to bedside necessitates innovations in manufacturing processes that can accommodate such personalized approaches at scale. Future research should focus on developing modular platforms that can be easily adapted to incorporate new discoveries and patient-specific data.

While technological advancements promise to enhance efficacy and safety, their real-world application raises significant economic and ethical questions. The high cost of these therapies remains a formidable barrier to access in low- and middle-income countries. Future initiatives should explore the development of cost-effective production methods such as the use of automated and decentralized manufacturing units. Ethically, there is a need to establish frameworks that ensure equitable access to these therapies globally, perhaps through international collaborations and policy reforms.

As CAR T-cell therapies evolve, so too must the regulatory frameworks that govern their development and deployment. The rapid pace of innovation challenges current regulatory paradigms, which are often ill-equipped to handle the nuances of advanced gene and cell therapies. An ongoing dialogue between regulators, researchers, and industry stakeholders is essential to develop more adaptive regulatory approaches that can keep pace with technological advancements while ensuring patient safety.

Looking forward, CAR T-cell therapies are expanding into exciting new territories. For autoimmune diseases, these therapies show promise in conditions like systemic lupus erythematous (173), multiple sclerosis (174) and type 1 diabetes (175), where they may modulate immune responses similarly to their actions against malignant cells. In the realm of aging and degenerative diseases, CAR T-cells are being investigated for their potential to modify the aging process and treat age-related ailments (176, 177). Additionally, the adaptation of CAR T-cell therapies for infectious diseases suggests a new frontier in managing chronic infections that resist conventional treatments (178). This expansion not only broadens the therapeutic potential of CAR T-cell therapies but also highlights the innovative cross-disciplinary approaches being undertaken to overcome current limitations and explore new applications.